Ribomic Inc
TSE:4591
Ribomic Inc
Other Items
Ribomic Inc
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ribomic Inc
TSE:4591
|
Other Items
¥200m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
SanBio Co Ltd
TSE:4592
|
Other Items
-¥298.2m
|
CAGR 3-Years
-179%
|
CAGR 5-Years
-394%
|
CAGR 10-Years
N/A
|
|
|
GNI Group Ltd
TSE:2160
|
Other Items
¥1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
PeptiDream Inc
TSE:4587
|
Other Items
-¥299.2m
|
CAGR 3-Years
77%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Takara Bio Inc
TSE:4974
|
Other Items
-¥6.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
O
|
Oncolys Biopharma Inc
TSE:4588
|
Other Items
-¥4.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
Ribomic Inc
Glance View
RIBOMIC, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for use in therapeutic fields. The company is headquartered in Minato-Ku, Tokyo-To and currently employs 25 full-time employees. The company went IPO on 2014-09-25. Its drug discovery business is divided into self discovery and co-discovery divisions. Self Drug Discovery division develops aptamer and licenses and out the results to pharmaceutical companies. The Co-Discovery division earns the research expenses paid by the alliance partner for the shared part of co-discovery business with alliance pharmaceutical companies researching aptamer pharmaceutical.
See Also
What is Ribomic Inc's Other Items?
Other Items
200m
JPY
Based on the financial report for Dec 31, 2025, Ribomic Inc's Other Items amounts to 200m JPY.
What is Ribomic Inc's Other Items growth rate?
Other Items CAGR 3Y
-34%
Over the last year, the Other Items growth was -33%. The average annual Other Items growth rates for Ribomic Inc have been -34% over the past three years .
